Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SB-4826 |
| Synonyms | |
| Therapy Description |
SB-4826 is a covalent inhibitor of SUMO E1, which may decrease sumoylation and increase IFN signaling, potentially leading to modulation of the tumor microenvironment and inhibition of tumor growth (Cancer Res 2023;83(8_Suppl):Abstract nr LB318). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SB-4826 | SB 4826|SB4826 | SB-4826 is a covalent inhibitor of SUMO E1, which may decrease sumoylation and increase IFN signaling, potentially leading to modulation of the tumor microenvironment and inhibition of tumor growth (Cancer Res 2023;83(8_Suppl):Abstract nr LB318). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07222631 | Phase Ib/II | SB-4826 Rituximab + SB-4826 | SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas | Not yet recruiting | USA | 0 |